ReviewJAAPA : official journal of the American Academy of Physician Assistants2026
Body dysmorphic disorder: Diagnostic challenges and current management.
Review in JAAPA : official journal of the American Academy of Physician Assistants, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
abstractBody dysmorphic disorder (BDD) is a psychiatric condition characterized by obsessive preoccupation with perceived flaws in appearance, causing significant dysfunction in daily life. BDD is often misdiagnosed due to patient concealment and its overlap with other mental health disorders. Increasing clinician awareness can overcome the diagnostic challenges presented by BDD. Early-onset BDD, particularly in adolescents, is associated with an increased risk of comorbidities and suicide. BDD may present with subthreshold symptoms before meeting full diagnostic criteria or before the patient discloses symptoms, creating an opportunity for earlier detection in primary and specialty care. Although first-line treatment consists of cognitive behavioral therapy and serotonin reuptake inhibitors, additional research and therapies are needed as many patients do not achieve full symptom remission. Early recognition and accurate diagnosis of BDD are vital for improving quality of life and optimizing long-term patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.